AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, messenger RNA (mRNA), plasmid DNA (pDNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
AGC Biologics Facility Expansion: Milan, Italy
AGC Biologics Heidelberg Site Expansion Tour
AGC Biologics Seattle Site - Mammalian Line C Tour
AGC Biologics Seattle | Mammalian & Microbial | Site Tour
AGC Biologics Seattle Facility - Microbial Line Tour
Upstream Process Optimization: Cell Line to Manufacturing Transfer
GMP-Focused Platform Processes for Microbial, pDNA and mRNA
AGC Biologics - Seattle GMP Warehouse Tour
AGC Biologics - Your Friendly CDMO Expert
The Changing CDMO Landscape: Single-use Technology, End-to-End Fill Finish Needs and More
AGC Biologics partnered with Gore PharmBIO to revolutionize antibody production
AGC Biologics Facility Grand Opening: Copenhagen Site Expansion, June 2024
Precision in Practice: Optimizing Large-Scale Mammalian Commercial Manufacturing
AGC Biologics CGT Process Development
AGC Biologics Copenhagen Mammalian Cell Culture Expansion 2023
CGT: Addressing Regulatory & Quality | AGC Biologics - ATMP Expert interview with Giuliana Vallanti
Creating New Standards in ATMP Manufacturing | AGC Biologics Expert Interview with Sabrina Cazzaniga
Building Standardized Viral Vector Platforms | AGC Biologics - Expert Interview with Margherita Neri
CGT: Addressing Regulatory & Quality | AGC Biologics - ATMP Expert interview with Giuliana Vallanti
Navigating the Changing ATMP Market | AGC Biologics ATMP Expert interview with Luca Alberici
Building Better Analytical Methods | AGC Biologics - ATMP Expert Interview with Francesca Rossetti
Delivering a GMP Process for ATMPs | AGC Biologics - ATMP Expert Interview with Francesca Bellintani
Addressing Cell Therapy Trends | AGC Biologics - ATMP Expert Interview with Alessandra Gatti
AGC Biologics Copenhagen | Mammalian and Microbial Biologics
AGC Biologics Milan | Cell Therapy and Viral Vectors
AGC Biologics Chiba | Mammalian & Microbial Biologics
AGC Biologics Heidelberg | Microbial biologics, pDNA & mRNA
AGC Biologics Longmont | Cell Therapy and Viral Vectors
AGC BIOLOGICS and the fight against COVID-19
Happy New Year 2021 from the AGC Bio Global Team